Malcovati L, Nimer SD. Myelodysplastic syndromes: Diagnosis and staging. Cancer Control 2008;15(Suppl.):4-13.
*Cazzola M, Malcovati L. Myelodysplastic syndromes - Coping with ineffective hematopoiesis. N Engl J Med 2005;352:536-8. (Pubitemid 40204666)
Mufti GJ. Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Best Pract Res Clin Haematol 2004;17:543-57. (Pubitemid 39378186)
Tassin F, Hermanne JP, Schaaf-Lafontaine N, et al. Myelodysplastic syndromes: Preleukemic syndromes. Rev Med Liège 1998;53:357-62.
Brunning RD, Germing U, Le Beau MM, et al. Myelodysplastic syndromes/neoplasms, overview. Lyon: IARC;2008.
Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99. (Pubitemid 12073508)
Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
*Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88. (Pubitemid 27132124)
**Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-10. (Pubitemid 47315575)
Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extrahematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011;96:441-9.
Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010;28:437-44.
Sekeres MA, Kantarjian H, Fenaux P, et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer 2011;117:992-1000.
Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: Results of a prospective randomized phase 3 trial by the Eastern cooperative oncology group (E1996). Blood 2009;114:2393-400.
Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: Proposal for a predictive model. Br J Haematol 1997;99:344-51. (Pubitemid 27497565)
Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life. Br J Haematol 2003;120:1037-46. (Pubitemid 36411563)
Greenberg PL. Myelodysplastic syndromes: Iron overload consequences and current chelating therapies. J Natl Compr Canc Netw 2006;4:91-6. (Pubitemid 44265384)
Stone RM. How I treat patients with myelodys-plastic syndromes. Blood 2009;113:6296-303.
de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic leukaemia working party of the European group for blood and marrow transplantation (EBMT). Br J Haematol 2000;110:620-30.
Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002;100:1997-2004. (Pubitemid 35001229)
Ho AYL, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004;104:1616-23. (Pubitemid 39202266)
Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006;108:836-46. (Pubitemid 44154615)
Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: Outcome analysis in 510 transplants facilitated by the National marrow donor program. Blood. 2002;99:1943-51. (Pubitemid 34525473)
Gardin C, Chaibi P, de Revel T, et al. Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de réflexion en hématologie. Leukemia 1997;11:16-21. (Pubitemid 27065044)
Ravandi F, Issa JP, Garcia-Manero G, et al. Hypomethylating therapy in patients with AML and high-risk MDS and chromosome 5 and 7 abnormalities is associated with an improved outcome compared to conventional chemotherapy. ASH Annual Meeting Abstracts 2008;112:2955.
Lim Z, Ho AYL, Samuel J, et al. Outcomes of MDS patients with chromosome 7 abnormalities treated with 5-Azacytidine. ASH Annual Meeting Abstracts. 2007;110:1449.
Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579-85. (Pubitemid 38900045)
Wattel E, de Botton S, Luc Lai J, et al. Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: Incidence of long-term survivors and outcome of partial responders. Br J Haematol 1997;98:983-91. (Pubitemid 27421645)
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32.
Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006;106:1794-803.
WijerMans P, Suciu S, Baila L, et al. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: Final results of the randomized phase III study (06011) of the EORTC Leukemia and German MDS study groups. ASH Annual Meeting Abstracts. 2008;112:226.
*List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-65. (Pubitemid 44511560)
Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111:86-93.
Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001;98:958-65.
Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008;26:2505-11.
Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 2007;21:1436-41. (Pubitemid 46965284)
